Takeda Pharmaceutical Co ADR (NYSE: TAK) started the day on Wednesday, with a price decrease of -0.59% at $13.57, before settling in for the price of $13.65 at the close. Taking a more long-term approach, TAK posted a 52-week range of $13.19-$17.11.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 14.64%. Meanwhile, its Annual Earning per share during the time was -6.94%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -59.28%. This publicly-traded company’s shares outstanding now amounts to $3.14 billion, simultaneously with a float of $3.14 billion. The organization now has a market capitalization sitting at $42.58 billion. At the time of writing, stock’s 50-day Moving Average stood at $14.32, while the 200-day Moving Average is $14.72.
Takeda Pharmaceutical Co ADR (TAK) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Drug Manufacturers – Specialty & Generic Industry. Takeda Pharmaceutical Co ADR’s current insider ownership accounts for 0.02%, in contrast to 5.45% institutional ownership. According to the most recent insider trade that took place on Jan 24 ’24, this organization’s 10% Owner sold 3,703,703 shares at the rate of 8.10, making the entire transaction reach 29,999,994 in total value, affecting insider ownership by 3,755,583.
Takeda Pharmaceutical Co ADR (TAK) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Takeda Pharmaceutical Co ADR’s EPS decrease for this current 12-month fiscal period is -59.28% and is forecasted to reach 0.47 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 0.02% through the next 5 years, which can be compared against the -6.94% growth it accomplished over the previous five years trading on the market.
Takeda Pharmaceutical Co ADR (NYSE: TAK) Trading Performance Indicators
Let’s observe the current performance indicators for Takeda Pharmaceutical Co ADR (TAK). It’s Quick Ratio in the last reported quarter now stands at 0.55. The Stock has managed to achieve an average true range (ATR) of 0.19. Alongside those numbers, its PE Ratio stands at $33.93, and its Beta score is 0.59. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.44. Similarly, its price to free cash flow for trailing twelve months is now 12.22.
In the same vein, TAK’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.40, a figure that is expected to reach -0.01 in the next quarter, and analysts are predicting that it will be 0.47 at the market close of one year from today.
Technical Analysis of Takeda Pharmaceutical Co ADR (TAK)
If we take a close look at the recent performances of Takeda Pharmaceutical Co ADR (NYSE: TAK), its last 5-days Average volume was 1.9 million that shows progress from its year to date volume of 1.84 million. During the previous 9 days, stock’s Stochastic %D was recorded 23.45% While, its Average True Range was 0.19.
Raw Stochastic average of Takeda Pharmaceutical Co ADR (TAK) in the period of the previous 100 days is set at 7.98%, which indicates a major fall in contrast to 11.93% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 16.73% that was higher than 15.44% volatility it exhibited in the past 100-days period.
